{
  "company": {
    "name": "Allakos",
    "website": "https://allakos.com/",
    "record": "https://startuphistory.org/c/allakos.com"
  },
  "status": null,
  "history_since": "2013-04-23T00:43:24.000Z",
  "baseline": {
    "snapshot_id": "66f1e18663678fc8820e59baebf879477b8ab7f136eb909340eaf52c59857910",
    "observed_at": "2016-02-25T04:13:19.000Z",
    "headline": null,
    "description": "biotechnology company developing antibodies targeting receptors that modulate the activity of immune effector cells involved in inflammation and tissue damage",
    "evidence": "https://web.archive.org/web/20160225041319/http://www.allakos.com:80/",
    "evidence_kind": "internet_archive",
    "facts": null,
    "basis": "first_observation",
    "is_change": false
  },
  "live_captures": 0,
  "last_checked": null,
  "live_status": "offline",
  "messaging": [
    {
      "quote_observed_at": "2023-01-28T07:33:41.000Z",
      "variants": [
        {
          "headline": "Allakos | AK002 mAb | Eosinophilic Gastroenteritis",
          "subhead": "Allakos is developing therapeutic antibodies that that selectively target eosinophils and mast cells, cells that play a significant role in many diseases",
          "observed_at": "2018-03-09T07:45:44.000Z",
          "evidence": "https://web.archive.org/web/20180309074544/http://www.allakos.com:80/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "Allakos | AK002 mAb | Eosinophilic Gastroenteritis",
          "subhead": "Allakos is developing therapeutic antibodies that that selectively target eosinophils and mast cells, cells that play a significant role in many diseases",
          "observed_at": "2019-02-12T01:26:33.000Z",
          "evidence": "https://web.archive.org/web/20190212012633/https://www.allakos.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "Allakos | AK002 mAb | Eosinophilic Gastroenteritis",
          "subhead": "Allakos is developing therapeutic antibodies that selectively target eosinophils and mast cells, cells that play a significant role in many diseases",
          "observed_at": "2020-10-01T07:12:57.000Z",
          "evidence": "https://web.archive.org/web/20201001071257/https://www.allakos.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "Allakos | AK002 mAb | Eosinophilic Gastroenteritis",
          "subhead": "Allakos is developing therapeutic antibodies that selectively target eosinophils and mast cells, cells that play a significant role in many diseases",
          "observed_at": "2021-09-28T10:18:06.000Z",
          "evidence": "https://web.archive.org/web/20210928101806/https://www.allakos.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "Allakos | AK002 mAb | Eosinophilic Gastroenteritis",
          "subhead": "Allakos is developing therapeutic antibodies that selectively target eosinophils and mast cells, cells that play a significant role in many diseases",
          "observed_at": "2023-01-28T07:33:41.000Z",
          "evidence": "https://web.archive.org/web/20230128073341/https://www.allakos.com/",
          "evidence_kind": "internet_archive"
        }
      ],
      "headline": "Allakos | AK002 mAb | Eosinophilic Gastroenteritis",
      "subhead": "Allakos is developing therapeutic antibodies that selectively target eosinophils and mast cells, cells that play a significant role in many diseases",
      "from": "2018-03-09T07:45:44.000Z",
      "to": "2023-01-28T07:33:41.000Z",
      "captures": 5,
      "evidence": "https://web.archive.org/web/20230128073341/https://www.allakos.com/",
      "evidence_kind": "internet_archive",
      "seen": {
        "between": {
          "from": "2018-03-09T07:45:44.000Z",
          "to": "2023-01-28T07:33:41.000Z"
        }
      },
      "current": false
    },
    {
      "quote_observed_at": "2025-04-22T06:04:50.000Z",
      "variants": [
        {
          "headline": "Allakos │ Therapeutic antibodies │ Mast cells and Eosinophils",
          "subhead": "Allakos is developing therapeutic antibodies that selectively target eosinophils and mast cells, cells that play a significant role in many diseases",
          "observed_at": "2024-02-24T08:59:55.000Z",
          "evidence": "https://web.archive.org/web/20240224085955/https://www.allakos.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "Allakos │ Therapeutic antibodies │ Mast cells and Eosinophils",
          "subhead": "Allakos is developing therapeutic antibodies that selectively target eosinophils and mast cells, cells that play a significant role in many diseases",
          "observed_at": "2025-01-25T22:13:13.000Z",
          "evidence": "https://web.archive.org/web/20250125221313/https://www.allakos.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "Allakos │ Therapeutic antibodies │ Mast cells and Eosinophils",
          "subhead": "Allakos is developing therapeutic antibodies that selectively target eosinophils and mast cells, cells that play a significant role in many diseases",
          "observed_at": "2025-04-22T06:04:50.000Z",
          "evidence": "https://web.archive.org/web/20250422060450/https://www.allakos.com/",
          "evidence_kind": "internet_archive"
        }
      ],
      "headline": "Allakos │ Therapeutic antibodies │ Mast cells and Eosinophils",
      "subhead": "Allakos is developing therapeutic antibodies that selectively target eosinophils and mast cells, cells that play a significant role in many diseases",
      "from": "2024-02-24T08:59:55.000Z",
      "to": "2025-04-22T06:04:50.000Z",
      "captures": 3,
      "evidence": "https://web.archive.org/web/20250422060450/https://www.allakos.com/",
      "evidence_kind": "internet_archive",
      "seen": {
        "between": {
          "from": "2024-02-24T08:59:55.000Z",
          "to": "2025-04-22T06:04:50.000Z"
        }
      },
      "current": true
    }
  ],
  "changes": [
    {
      "n": 1,
      "id": "page-187a7e05d032ea1598da774f9447aecf0185a93dbf250880a42e606c483f7dfc:dc3f12447a88f788281828e3d1bc25dd385304c5f64d288acb9f78dbaef677c8:headline:c7bee144735038be",
      "before_evidence": "https://web.archive.org/web/20230128073341/https://www.allakos.com/",
      "before_evidence_kind": "internet_archive",
      "kind": "headline",
      "label": "Headline",
      "summary": "Changed its homepage headline from “Allakos | AK002 mAb | Eosinophilic Gastroenteritis” to “Allakos │ Therapeutic antibodies │ Mast cells and Eosinophils”.",
      "between": {
        "from": "2023-01-28T07:33:41.000Z",
        "to": "2024-02-24T08:59:55.000Z"
      },
      "evidence": "https://web.archive.org/web/20240224085955/https://www.allakos.com/",
      "evidence_kind": "internet_archive",
      "basis": "page_facts",
      "topic": null
    }
  ],
  "update": null,
  "method": {
    "version": "messaging-v1",
    "description": "https://startuphistory.org/method"
  },
  "license": "CC-BY-4.0",
  "cite": "StartupHistory, “Allakos” company record, https://startuphistory.org/c/allakos.com"
}